Intervention

Ponatinib

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 5 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials5

Recruiting0

Common conditions25

Lead sponsors shown5

Clinical trials

5 shown

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyNCT04591431 · 2020-10-07

UNKNOWN

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01

TERMINATED

Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid LeukemiaNCT04043676 · 2019-04-30

UNKNOWN

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive BiomarkersNCT01935336 · 2013-09-24

COMPLETED

Ponatinib in Advanced NSCLC w/ RET TranslocationsNCT01813734 · 2013-09-01

COMPLETED

Common conditions

Non Small Cell Lung Cancer2 Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1 Adenocarcinoma of the Lung1 Anatomic Stage IV Breast Cancer AJCC v81 Anemia1 Ann Arbor Stage III Hodgkin Lymphoma1 Ann Arbor Stage III Non-Hodgkin Lymphoma1 Ann Arbor Stage IV Hodgkin Lymphoma1 Ann Arbor Stage IV Non-Hodgkin Lymphoma1 Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative1 Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1 Breast Cancer1 Castration-Resistant Prostate Carcinoma1 Chronic Myeloid Leukemia1 Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1 Extensive Stage Small Cell Lung Cancer1 Gastrointestinal Cancer1 Hematopoietic and Lymphoid System Neoplasm1 Limited Stage Small Cell Lung Cancer1 Locally Advanced Pancreatic Adenocarcinoma1 Metastatic Breast Carcinoma1 Metastatic Malignant Solid Neoplasm1 Metastatic Pancreatic Adenocarcinoma1 Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis1 Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable1

Leading sponsors

Fondazione per la Medicina Personalizzata 1 Fundación Teófilo Hernando, Spain 1 Massachusetts General Hospital 1 OHSU Knight Cancer Institute 1 University of Colorado, Denver 1

Trial status mix

COMPLETED2

UNKNOWN2

TERMINATED1

Phase mix

PHASE24

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.